Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy

Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy

BackgroundNon-small cell lung cancer (NSCLC) patients treated with first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) almost always acquire resistance, and the development of novel techniques analyzing circulating tumor DNA (ctDNA) have made it possible for liquid...

Full description

Bibliographic Details
Main Authors: Yulong Fu, Anqi Wang, Jieqi Zhou, Wei Feng, Minhua Shi, Xiao Xu, Hongqing Zhao, Liming Cai, Jian Feng, Xuedong Lv, Xiaodong Zhang, Wenjing Xu, Zhengrong Zhang, Guoer Ma, Jian Wang, Tong Zhou, Dahai Zhao, Haohui Fang, Zeyi Liu, Jian-an Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
liquid biopsy
gene sequencing
epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)
drug resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.621992/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.621992/full

Similar Items